Blood caspase-8 concentrations and mortality among septic patients.


Journal

Medicina intensiva
ISSN: 2173-5727
Titre abrégé: Med Intensiva (Engl Ed)
Pays: Spain
ID NLM: 101717568

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 19 04 2020
accepted: 27 06 2020
entrez: 7 1 2022
pubmed: 8 1 2022
medline: 1 2 2022
Statut: ppublish

Résumé

No data are available on blood caspase-8 concentrations (the initiator caspase in the extrinsic apoptosis pathway) in septic patients. The present study thus describes the blood caspase-8 concentrations in survivors and non-survivors, and examines the possible association between blood caspase-8 concentrations and mortality in septic patients. A prospective observational study was carried out. Three Spanish Intensive Care Units. Septic patients. Serum caspase-8 concentrations were determined at the diagnosis of sepsis. Mortality after 30 days. Patients not surviving at day 30 (n=81) compared to surviving patients (n=140) showed higher serum caspase-8 levels (p<0.001). Multiple logistic regression analysis found an association between serum caspase-8 levels>43.5ng/ml and mortality (OR=3.306; 95%CI=1.619-6.753; p=0.001). The area under the curve (AUC) for mortality predicted by serum caspase-8 levels was 67% (95% CI=60-73%; p<0.001). The novel findings of our study were that blood caspase-8 concentrations are higher in non-survivors than in survivors, and that there is an association between blood caspase-8 concentrations and mortality in septic patients.

Identifiants

pubmed: 34991877
pii: S2173-5727(21)00188-0
doi: 10.1016/j.medine.2020.06.015
pii:
doi:

Substances chimiques

CASP8 protein, human EC 3.4.22.-
Caspase 8 EC 3.4.22.-

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-13

Informations de copyright

Copyright © 2020 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Auteurs

L Lorente (L)

Intensive Care Unit, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Tenerife, Spain. Electronic address: lorentemartin@msn.com.

M M Martín (MM)

Intensive Care Unit, Hospital Universitario Nuestra Señora Candelaria, Crta Rosario s/n., Santa Cruz Tenerife 38010, Spain.

R Ortiz-López (R)

Intensive Care Unit, Hospital General de La Palma, Buenavista de Arriba s/n, Breña Alta, La Palma 38713, Spain.

A F González-Rivero (AF)

Laboratory Department, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain.

A Pérez-Cejas (A)

Laboratory Department, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Tenerife, Spain.

M Martín (M)

Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n., La Laguna, Santa Cruz de Tenerife 38320, Spain.

V Gonzalez (V)

Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n., La Laguna, Santa Cruz de Tenerife 38320, Spain.

A Pérez (A)

Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n., La Laguna, Santa Cruz de Tenerife 38320, Spain.

M Rodin (M)

Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n., La Laguna, Santa Cruz de Tenerife 38320, Spain.

A Jiménez (A)

Research Unit, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Tenerife, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH